Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen-pulsed dendritic cell vaccine plus chemotherapy for advanced pancreatic cancer
jRCTc030190081Suspended
- Start
- Mar 2020
- Modality
- Small Molecules, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of Neo-DCVac, gemcitabine, paclitaxel and FOLFIRINOX in pancreatic cancer (PC) (2 arms). Primary endpoint: Safety and toxicity. Started Mar 2020; status: suspended.
02
Drugs
Neo-DCVacgemcitabinepaclitaxelFOLFIRINOX
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTc030190081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTc030190081.